Zvia Agur

Professor Zvia Agur is an eminent international biomathematician, who has made major contributions to the theory of disease dynamics, chemotherapy and vaccination policies optimization. Prof. Agur is founder of the Institute for Medical BioMathematics (IMBM), has been the president of the Israeli Society of Theoretical and Mathematical Biology, a member of the Board of Directors of the European Society of Mathematical and Theoretical Biology, and an editor of several professional publications. Her innovative research work has won national awards, has been published in a long line of leading scientific journals and is recognized by the academic community worldwide. Prof. Agur holds a Ph.D. from the Hebrew University in Jerusalem and the Université Libre in Brussels.

 

Education and Positions:

2000

Chairperson & CSO, Optimata Ltd

1999

President, Institute for Medical Biomathematics (IMBM)

1994-9  

Associate Professor, Cell Research and Immunology, Tel-Aviv University, Israel

1987-4  

Senior Scientist, Weizmann Institute of Science, Rehovot, Israel

1982

Ph.D., Biomathematics, Université Libre, Belgium

1974

M,Sc studies in Philosophy of Science from the Hebrew University

1973

M.Sc., Genetics from the Hebrew University

1971

B.Sc, Genetics and Microbiology, from the Hebrew University

 

Visiting Scientist:

1992-4 

Oxford University, UK

1991 

Imperial College of Science, UK

1989 

Ecole Normale Superieure, Paris

1989 

Rockefeller University, New York, USA

1985 

University of New York at Stoney Brook, USA

 

Activity on Professional Societies:

1998-01

President of the Israeli Society of Theoretical and Mathematical Biology. (ISMTB)

1997-03

Board of Directors of the European Society of Mathematical and Theoretical Biology (ESMTB)

1996-8

Acting President of the Israeli Society of Theoretical and Mathematical Biology (ISMTB)

1991

Member of the European Society of Mathematics in Biology and Medicine (ESMTB)

1986

Member of the Society of Mathematical Biology (SMB)

 

Academic and Professional Awards:

2016

Finalist for EU Prize for Women Innovators, European Commission.

2004

Best Paper Award, 6th International Conference on Cellular Automata for Research and Industry, ACRI.

1989  

The Juludan Prize for Outstanding Scientific Achievements, Technion — Israel Institute of Technology, Haifa

1987  

Jakubskind-Cymerman Research Prize, The Weizmann Institute of Science, Rehovot, Israel

1987

The Elaine Blond Career Development Chair, The Weizmann Institute of Science, Rehovot, Israel

1974

Aharon Katzir Prize for Scientific Writing, Israel Academy of Science, Israel

 

Editorial Boards:

2012

Current Angiogenesis Editorial Board Member

2010

Computational and Mathematical Methods in Medicine- Editorial Board Member

2006

Mathematical Modelling of Natural Phenomena- Editorial Board Member on Hematopoiesis and blood diseases

2000-08

Associate Editor-Journal of M3AS, Mathematical Methods and Models in the Applied Sciences / World Scientific Singapore. New Jersey. London. Hong Kong.

1998

Associate Editor – Book Series in Mathematical and Computational Biology. Wiley, UK

1997-8

Guest Associate Editor – Jour. Mathematical Bioscience / Elsevier.

1996

Associate Editor – Jour. of Biological Systems / World Scientific Singapore. New Jersey. London. Hong Kong.

 

Recent Selected Publications:

  1. Agur Z, Elishmereni M, Foryś U, Kogan Y. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients’ Profiles with Dynamic Mathematical Models. Clinical Pharmacology & Therapeutics. doi: https://doi.org/10.1002/CPT.1942.
  2. Perlstein D, Shlagman O, Kogan Y, Halevi-Tobias K, Yakobson A, Lazarev I, et al. Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug. PLoS One. 2019;14(12):e0226869. doi: 10.1371/journal.pone.0226869. PubMed PMID: 31877168.
  3. Tsur N, Kogan Y, Rehm M, Agur Z. Response of Patients with Melanoma to Immune Checkpoint Blockade – Insights Gleaned from Analysis of a New Mathematical Mechanistic Model. J Journal of Theoretical Biology 2019:110033. doi: 10.1016/j.jtbi.2019.110033. PubMed PMID: 31580835.   
  4. Tsur N, Kogan Y, Avizov-Khodak E, Vaeth D, Vogler N, Utikal J, Lotem M, Agur Z. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. J Journal of Translational Medicine 2019;17(1):338. doi: 10.1186/s12967-019-2081-2. PubMed PMID: 31590677.
  5. Gillis A, Beil M, Halevi-Tobias K, van Heerden PV, Sviri S, Agur Z. Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics—analysis of a new mathematical model. J Intensive Care Medicine Experimental. 2019 7(1):32. doi: 10.1186/s40635-019-0260-3.    
  6. Hochman G, Halevi-Tobias K, Kogan Y, Agur Z. Extracellular inhibitors can attenuate tumorigenic Wnt pathway activity in adenomatous polyposis coli mutants: Predictions of a validated mathematical model. J PLoS One 2017 Jul 14;12(7):e0179888.
  7. Agur Z, Halevi-Tobias K, Kogan Y & Shlagman O. Employing dynamical computational models for personalizing cancer immunotherapy. Expert Opin Biol Ther., 26, 2016, pp 1-13.
  8. Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z. Prediction of individual response to androgen deprivation therapy in hormone sensitive prostate cancer stage patients by integrating a mathematical mechanistic model of tumor progression with clinical patient characteristics. Prostate, 76(1), 2016, pp 48-57.